Bcl-x_S/L Lentiviral Activation Particles (h2): sc-400170-LAC-2

Human BCL2L1 encodes the Bcl-xS/L isoforms, alternatively spliced BCL-2 family regulators that tune mitochondrial outer membrane permeabilization and caspase activation by balancing anti-apoptotic Bcl-xL and pro-apoptotic Bcl-xS activities. Bcl-x proteins integrate survival and stress cues across the intrinsic apoptosis pathway, intersecting with p53 signaling, MAPK/AKT-mediated survival programs, calcium homeostasis, and autophagy/mitophagy to shape cell fate decisions and mitochondrial dynamics. Dysregulated BCL2L1 expression or splicing is frequently associated with altered apoptosis thresholds in cancer, inflammatory conditions, and neurodegeneration, where shifts in isoform ratio can influence resistance to cell death and tissue homeostasis. Gene editing of BCL2L1 enables mechanistic studies of isoform-specific function, splicing control, and protein–protein interactions with BH3-only factors, supporting functional genomics screens, pathway dissection, and the development of disease-relevant cellular models.

Bcl-xS/L Lentiviral Activation Particles (h2) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient BCL2L1 upregulation across a broader range of human cell types.

Bcl-xS/L Lentiviral Activation Particles (h2) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the BCL2L1 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous Bcl-xS/L expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native BCL2L1 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.